- Global Pharma News & Resources

Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021

Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021

Oslo, Norway, 7 December 2021

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 8 December at the 3rd Targeted Radiopharmaceutical Summit 2021 event (7-9 December 2021).

The presentation slides will be available on 8 December at 17:00 CET at in the section: Investors & Media/Reports and Presentations.

Presentation details are as follows:

Title: Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates

Date/time: Wednesday, 8 December 2021 at 17:00 CET

During his presentation, Dr Dahle will cover the following points:

  • Review CD37 as an important, validated, yet underexploited target for radioimmunotherapy, highlighting its exclusive expression on B cells at similar levels and across similar B cell lineages as CD20 and CD19, both of which are the basis of existing immunotherapies and cell therapies for Non-Hodgkin's Lymphoma (NHL) 
  • Analyse data from clinical studies with Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmunoconjugate that has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments. Betalutin® is currently being investigated in the pivotal Phase 2b PARADGIME trial, with preliminary three-month data expected in 1H 2022
  • Evaluate preclinical data with Alpha37 (212Pb-TCMC-NNV003*), an anti-CD37 alpha-emitting radioimmunoconjugate, which has shown strong anti-tumour effects in ibrutinib-sensitive and -resistant models of Chronic Lymphocytic Leukaemia and NHL under a collaboration with Orano Med

The 3rd Targeted Radiopharmaceutical Summit is an industry-leading conference and includes expert speakers and stakeholders from major companies in the field. The summit seeks out solutions to longstanding obstacles in radiopharmaceutical development at all stages, from bench to bedside.

*TCMC is used to chelate lead-212 (212Pb) to NNV003, a chimeric anti-CD37 antibody developed by Nordic Nanovector.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762

Editor Details

Last Updated: 09-Dec-2021